ArticleScientific reports2018
Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- From "immune silence" to "immune dialogue": modification strategies for bone substitutes based on bone immunomodulatory characteristics.Frontiers in cell and developmental biology · 2025Review
- Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering.Nature communications · 2024Article
- Elevated BMPR2 expression amplifies osteoblast differentiation in ankylosing spondylitis.Journal of rheumatic diseases · 2023Article
- Rationally designed bioactive milk-derived protein scaffolds enhanced new bone formation.Bioactive materials · 2023Article
- Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms.Current rheumatology reports · 2022Review
- Osteogenic Efficacy of Human Trophoblasts-Derived Conditioned Medium on Mesenchymal Stem Cells.International journal of molecular sciences · 2022Article
- Bone Involvement in Patients with Spondyloarthropathies.Calcified tissue international · 2022Review
- Macrophage-like Cells Are Responsive to Titania Nanotube Intertube Spacing-An In Vitro Study.International journal of molecular sciences · 2022Article
- Regulation of the mesenchymal stem cell fate by interleukin-17: Implications in osteogenic differentiation.World journal of stem cells · 2021Review
- Synthetic ceramic macroporous blocks as a scaffold in ectopic bone formation induced by recombinant human bone morphogenetic protein 6 within autologous blood coagulum in rats.International orthopaedics · 2021Article
- Regulation of Osteoblast Differentiation by Cytokine Networks.International journal of molecular sciences · 2021Review
- The State of the Art and Prospects for Osteoimmunomodulatory Biomaterials.Materials (Basel, Switzerland) · 2021Review
- Use of Therapeutic Pathogen Recognition Receptor Ligands for Osteo-Immunomodulation.Materials (Basel, Switzerland) · 2021Article
- The Role of the Immune Microenvironment in Bone Regeneration.International journal of medical sciences · 2021Review
- The Interrelationship Between Diabetes, IL-17 and Bone Loss.Current osteoporosis reports · 2020Review
- The Adenosine A2A Receptor Agonist Accelerates Bone Healing and Adjusts Treg/Th17 Cell Balance through Interleukin 6.BioMed research international · 2020Article
- Impact of Bacterial Infections on Osteogenesis: Evidence From In Vivo Studies.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin 17 (IL-17) stimulates the osteogenic differentiation of progenitor cells in vitro through a synergy with bone morphogenetic protein (BMP)-2. This study investigates whether the diverse responses mediated by IL-17 in vivo also lead to enhanced BMP-2-induced bone formation. Since IL-17 is known to induce osteoclastogenesis, we studied the interactions between IL-17 and BMP-2 in ceramic scaffolds either or not carrying a coating with the bisphosphonate zoledronic acid (ZOL). Histological evaluation revealed that IL-17 alone did not induce any osteoclasts at day 10. On the other hand, BMP-2 clearly stimulated early tissue ingrowth and osteoclastogenesis. Both of these processes were blocked in presence of ZOL. IL-17 signaling restored early vascularized connective tissue formation and osteoclastogenesis induced by BMP-2 in ZOL-coated scaffolds. After 12 weeks, the bone volume induced by co-delivery of BMP-2 and IL-17 was doubled as compared to that induced by BMP-2 alone. We conclude that IL-17 has osteo-stimulatory effects through a synergy with bone-inductive BMP-2. Although local and single application of IL-17 does not mediate osteoclast formation, it could promote other processes involved in bone formation such as connective tissue ingrowth. The use of IL-17 may contribute to the development of improved bone graft substitutes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.